How Long Does Semaglutide Take to Suppress Appetite? The Hunger Curve, Week by Week

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Semaglutide appetite reduction typically begins between weeks 1 and 4, with the most decisive shift usually appearing after the 0.5 mg dose increase at week 5
• The 0.25 mg starting dose is sub-therapeutic for many patients; little or no appetite change at this dose is not a treatment failure signal
• Food noise reduction is the most distinctive subjective effect, often noticed before any scale movement
• The 7-day half-life produces stable appetite effect across the dosing week, with most patients describing little fluctuation between injections at maintenance dose
• Approximately 15 to 30 percent of patients show limited appetite response despite adequate dose and adherence; tirzepatide is the most common next-step option

Direct answer

Most patients notice semaglutide's appetite-suppressing effect within 1 to 4 weeks of the first injection. The clearest change typically appears between weeks 2 and 8, often coinciding with the move from 0.25 mg to 0.5 mg or 1 mg. Food noise reduction is usually the first conscious sign; reduced portion sizes and longer gaps between meals follow. Full appetite effect at a stable dose takes 4 to 5 weeks of consistent dosing because of the drug's 7-day half-life.

Table of contents

1. The shape of semaglutide appetite suppression
2. How GLP-1 signaling affects hunger circuits
3. Week-by-week timeline with dose milestones
4. The four components of appetite that respond
5. Why the 0.25 mg dose mostly doesn't suppress appetite
6. The 0.5 mg threshold
7. The 1 mg and 2.4 mg differences
8. Appetite effect across the 7-day week
9. Fast and slow responders
10. Decision framework: tracking appetite response
11. Contrary view: how much of "appetite suppression" is the gut and how much is the brain
12. FAQ
13. Sources

The shape of semaglutide appetite suppression

Semaglutide does not flip appetite off like a switch. The change builds over weeks, intensifies at each dose step, and reaches a stable plateau at maintenance dose. The arc is roughly logarithmic: large early gains, diminishing returns at higher doses.

For most patients, the curve looks like this:

• Week 1: little change for most patients
• Week 2 to 4: subtle changes for many; clear changes for some
• Week 5 to 8: pronounced changes for most patients after 0.5 mg increase
• Week 9 to 16: maximum subjective change as 1 mg and 1.7 mg are reached
• Week 17 onward at 2.4 mg: stable appetite suppression, modest additional gain over 1.7 mg

How GLP-1 signaling affects hunger circuits

GLP-1 acts at multiple sites involved in appetite regulation.

In the arcuate nucleus of the hypothalamus, GLP-1 receptor activation reduces signaling from the agouti-related peptide and neuropeptide Y neurons that drive hunger. This produces a baseline reduction in hunger drive.

In the area postrema and nucleus tractus solitarius (brainstem regions involved in satiety and nausea), GLP-1 activation amplifies satiety signaling. This is why meals feel filling sooner.

In the ventral tegmental area and nucleus accumbens (reward circuits), GLP-1 activation appears to dampen the rewarding value of food. This is why cravings and food noise drop.

In the stomach and proximal small intestine, GLP-1 slows gastric emptying. Food sits in the stomach longer, prolonging fullness signals and reducing the speed at which glucose enters circulation.

All four effects build with sustained receptor engagement. None of them produces full strength on day one of treatment.

Week-by-week timeline with dose milestones

Week	Dose (standard)	Typical appetite experience
1	0.25 mg	Possible mild nausea days 1-3; minimal appetite shift for most
2-3	0.25 mg	Some patients notice food noise quieting; smaller portions feel adequate
4	0.25 mg	Last week at starter dose; clearer appetite signal for responders
5-8	0.5 mg	Pronounced appetite reduction for most patients; portions shrink; cravings dampen
9-12	1 mg	Strong appetite effect; food noise often gone; meal anticipation flattens
13-16	1.7 mg (Wegovy step)	Maximum appetite effect for many; further dose has smaller marginal benefit
17+	2.4 mg (Wegovy maintenance)	Stable appetite suppression; some additional gain over 1.7 mg

The four components of appetite that respond

Patient-reported appetite changes on semaglutide can be sorted into four buckets:

Hunger. The physical, body-located sensation of needing to eat. Typically drops between weeks 2 and 6. Patients describe going from "ravenous by 11 a.m." to "forgetting lunch."

Satiety. The fullness signal that ends a meal. Arrives sooner, more decisively, and lasts longer. Patients describe putting down the fork halfway through a meal that previously would have been finished.

Food noise. The mental engagement with food outside of physical hunger. The most striking change for many patients, often described in dramatic terms ("the radio in my head turned off").

Reward sensitivity. The pleasure or anticipated pleasure of eating. Flattens for many patients. Previously irresistible foods become uninteresting. Some patients describe a mild aversion to highly fatty or sweet foods.

Different patients experience different combinations of these four. A patient might have strong food noise reduction with minimal satiety change, or vice versa. The aggregate "appetite suppression" is the sum.

Why the 0.25 mg dose mostly doesn't suppress appetite

The starting dose of 0.25 mg is one-tenth the maximum Wegovy dose. It exists for tolerability, not therapeutic effect.

At 0.25 mg, GLP-1 receptor occupancy in the central nervous system is modest. Enough to produce some glucose effect (because pancreatic beta cells are highly responsive), but typically not enough to produce strong appetite suppression in the brain.

A subset of patients does feel appetite change at 0.25 mg, particularly those with strong baseline receptor sensitivity. The majority do not. The 4-week minimum at this dose is for gut adaptation; the appetite effect waits for higher doses.

The 0.5 mg threshold

The 0.5 mg dose is the first dose at which semaglutide reliably produces appetite suppression in most patients. For Ozempic, 0.5 mg is the starting therapeutic dose for type 2 diabetes. For Wegovy, it's the second titration step.

Patients who reach 0.5 mg at week 5 typically describe clear changes by week 6 or 7, after the first full week of new steady-state concentration. The food noise drop often crystallizes at this dose.

Weight loss usually begins or accelerates at this point. The combination of reduced food noise, smaller portions, and longer between-meal intervals produces a real caloric deficit for the first time in most patients.

The 1 mg and 2.4 mg differences

At 1 mg, appetite effect intensifies. Many patients describe forgetting to eat. Family members start commenting on portion sizes. Cravings for previously craved foods drop.

At 1.7 mg and 2.4 mg (Wegovy doses, above the Ozempic ceiling), the appetite effect plateaus for many patients. The marginal gain from 1 mg to 2.4 mg is real but smaller than the gain from 0.5 mg to 1 mg. The additional dose produces more side effects in some patients without proportionally more appetite benefit.

The clinical takeaway: patients with adequate response at 1 mg do not necessarily need to push to 2.4 mg. Some do, particularly those still hungry at 1 mg or those with weight loss plateauing below target. Others stay at 1 mg indefinitely with good results.

Appetite effect across the 7-day week

Semaglutide's half-life of approximately 7 days produces relatively stable plasma concentrations across the week between injections. Most patients describe appetite effect as steady from day to day.

A minority of patients report stronger appetite suppression in the first 3 to 4 days after injection and slightly less in days 5 to 7. This is more common at lower doses (where the trough concentration may dip below the appetite-effect threshold) and less common at maintenance doses (where receptor saturation is more complete throughout the cycle).

Some patients adjust injection timing strategically. Injecting before a typically high-eating weekend, for instance, can align peak appetite effect with the riskiest period. Clinical evidence for this practice is anecdotal but the pharmacokinetic logic is sound.

Fast and slow responders

Fast responders describe substantial appetite suppression within the first week or two at 0.25 mg. The mechanism is not fully characterized; likely involves higher baseline central GLP-1 receptor density or stronger central nervous system penetration.

Slow responders or non-responders show limited appetite change even at maintenance dose. Estimates from real-world data put this group at 15 to 30 percent of patients. The factors that distinguish responders from non-responders are not reliably predictable in advance.

For non-responders, switching to tirzepatide is the most common next step. SURPASS-2 head-to-head data and observational comparisons consistently show tirzepatide produces meaningful response in many semaglutide non-responders, likely because the dual GIP/GLP-1 mechanism engages an additional pathway.

Decision framework: tracking appetite response

Useful metrics to track from baseline:

• Daily hunger rating (1 to 10) averaged across the day
• Time-spent-thinking-about-food in rough hours per day
• Portion size satisfaction rating
• Number of eating occasions per day
• Craving frequency and intensity

Evaluate at standard milestones:

• Week 4 (last week of 0.25 mg): expect modest change at most; absence of change is not concerning
• Week 8 (after 4 weeks at 0.5 mg): expect meaningful change in 2 to 3 metrics for responders
• Week 12 (after 4 weeks at 1 mg): expect substantial change across most metrics for responders
• Week 16 to 20: re-evaluate response and dose if appetite has not shifted meaningfully

Contrary view: how much of "appetite suppression" is the gut and how much is the brain

Patient reports tend to describe semaglutide's effect in central terms: food noise, cravings, reward. The mechanism most clearly characterized in research is peripheral: slowed gastric emptying.

Slowed gastric emptying alone can produce many of the effects patients attribute to "appetite suppression." Food stays in the stomach longer, so satiety signals last longer. Eating a large portion produces stronger discomfort, which conditions behavior toward smaller portions. Reduced glucose excursions reduce post-meal reactive hunger.

The central effects are real (animal models clearly demonstrate hypothalamic and reward-circuit involvement), but the contribution of peripheral slowing to the overall subjective experience may be larger than patient reports suggest. Patients describe a brain change because that's what consciousness sees; the underlying biology may be more peripheral than the experience implies.

This is not a contradiction of the patient experience. It's a note that the mechanism is more layered than the simple "the drug turns off hunger in your brain" framing.

FAQ

What is the short answer for How Long Does Semaglutide Take to Suppress Appetite? The Hunger Curve, Week by Week?

Most patients notice semaglutide's appetite-suppressing effect within 1 to 4 weeks of the first injection. The clearest change typically appears between weeks 2 and 8, often coinciding with the move from 0.25 mg to 0.5 mg or 1 mg. Food noise reduction is usually the first conscious sign; reduced portion sizes and longer gaps between meals follow. Full appetite effect at a stable dose takes 4 to 5 weeks of consistent dosing because of the drug's 7-day half-life.

What should patients track during the first few weeks?

Track dose date, appetite change, weight trend, nausea, bowel habits, hydration, sleep, and any symptom that changes after a dose increase.

When should the prescriber be involved?

Contact the prescribing clinician if symptoms are severe, persistent, worsening after titration, or paired with dehydration, abdominal pain, vomiting, low blood sugar, or medication-timing confusion.

Does this replace the medication label?

No. Use the FDA label, pharmacy instructions, and your prescriber's written plan first. This page explains the timing pattern behind how long does it take for semaglutide to suppress appetite.

Why do timelines vary between patients?

Timelines vary because dose escalation, starting weight, diabetes status, other medications, food intake, gastric emptying, and side-effect sensitivity differ from person to person.

What is the safest way to use this information?

Use it to set expectations and ask better questions, not to change a dose, skip a dose, restart after a break, or combine medications without medical guidance.

Related guides

• How Long Does Tirzepatide Take to Suppress Appetite? Mapping the Food Noise Drop
• How Long Does Ozempic Take to Work? A Week-by-Week Patient Map
• How Long Does It Take for Wegovy to Work? Mapping the STEP 1 Curve to Your Calendar
• How Long Does Wegovy Stay in Your System? Clearance, Appetite Return, and the Regain Trajectory
• How Long Can Compounded Semaglutide Be Out of the Fridge? Beyond-Use Dating Explained
• How Long Does It Take for Ozempic to Work? The Phased Timeline
• Tool: weight-loss timeline tool

Sources

1. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384(11):989-1002.
2. Davies M, et al. STEP 2. Lancet. 2021;397(10278):971-984.
3. Frias JP, et al. SURPASS-2. N Engl J Med. 2021;385(6):503-515.
4. Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387(3):205-216.
5. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metab. 2018;27(4):740-756.
6. Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66-70.
7. Hsu TM, et al. Hippocampus ghrelin signaling mediates appetite responses. Diabetes. 2018.
8. Knudsen LB, Lau J. Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
9. FDA. Wegovy Prescribing Information. Updated 2024.
10. FDA. Ozempic Prescribing Information. Updated 2024.
11. Endocrine Society. Pharmacological Management of Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends operates as a telehealth platform that facilitates patient access to licensed independent clinicians. Content here is educational; it is not a substitute for personalized clinical evaluation.

Compounded Medication Notice. FormBlends prescribes compounded semaglutide and tirzepatide dispensed by 503A pharmacies. Compounded medications are not FDA-approved and are not therapeutically equivalent to brand Ozempic, Wegovy, Mounjaro, or Zepbound.

Results Disclaimer. Appetite responses summarized above reflect typical patterns. Individual response varies; some patients experience effects at the starter dose, others not until higher doses, and a meaningful fraction show limited response despite adequate dose.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with these brand holders.